Total Long-Term Liabilities

The following section summarizes insights on 's Total Long-Term Liabilities:

• Inozyme Pharma Inc's latest twelve months diluted eps incl extra items is -1.62
• Inozyme Pharma Inc's diluted eps incl extra items for fiscal years ending December 2020 to 2024 averaged -2.46.
• Inozyme Pharma Inc's operated at median diluted eps incl extra items of -1.78 from fiscal years ending December 2020 to 2024.
• Looking back at the last 5 years, Inozyme Pharma Inc's diluted eps incl extra items peaked in December 2023 at -1.37.
• Inozyme Pharma Inc's diluted eps incl extra items hit its 5-year low in December 2020 of -5.11.
• Inozyme Pharma Inc's diluted eps incl extra items decreased in 2024 (-1.62, +18.3%) and increased in 2020 (-5.11, -69.3%), 2021 (-2.40, -53.0%), 2022 (-1.78, -26.1%), and 2023 (-1.37, -22.7%).